Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

This article explains how stability studies GMP support shelf life justification during inspections. It examines pharmaceutical stability testing, ongoing stability programs, and common GMP inspection observations when expiration date assignment lacks scientific or regulatory support.
GMP did not emerge by chance. This article traces the history of GMP regulations, key enforcement milestones, and regulatory inspection evolution that shaped modern pharmaceutical manufacturing standards and quality systems still used to assess compliance today.
GMP inspections increasingly focus on supplier oversight and audit execution. This article explains how vendor audit programs, supplier qualification, and risk-based evaluation influence inspection outcomes and how inspection-ready audit checklists strengthen GMP supplier control systems.
GMP inspections increasingly rely on documentation quality to judge system control. This article explains how regulators assess GMP records, data integrity, and traceability, and how inspection-ready documentation systems reduce audit findings and escalation risk.
Explore how adverse drug reactions evolve across the pharmacovigilance lifecycle, highlighting post-marketing safety, inspection-sensitive gaps, and structured workflows that ensure regulatory compliance, traceable oversight, and proactive risk management for pharmaceutical teams.
A practical overview of the pharmacovigilance lifecycle, explaining how clinical safety monitoring, signal detection, and risk management planning evolve from pre-marketing activities to post-marketing oversight under current GVP compliance and regulatory inspection expectations.
This article explains why ISO-certified pharmaceutical organizations still face GMP inspection findings, how regulators interpret GMP versus ISO in practice, and what inspection-driven quality oversight requires beyond certification to achieve true regulatory inspection readiness.
The ISO 9001 2026 revision is underway, introducing modern elements such as digital systems, ESG principles, and enhanced risk and resilience guidance. This article provides an overview of the upcoming changes and what organizations should expect.
The pharmaceutical industry is under growing scrutiny from regulators when it comes to CAPA effectiveness checks. This blog explores how to improve root cause analysis, ensure closed-loop CAPA systems, and avoid repeat findings in GMP audits.
Discover how working standards uphold quality, safety, and regulatory compliance in the pharmaceutical industry. Explore key components and best practices.